BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Forest Laboratories, Inc. (FRX) Receives Non-Approvable Letter For Social Anxiety Disorder Indication For Lexapro(R)


10/19/2005 5:13:10 PM

NEW YORK, March 30 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. announced today that the U.S. Food and Drug Administration (FDA), following its initial review of a supplemental New Drug Application for Lexapro (R) (excitalopram oxalate), an SSRI antidepressant, for the treatment of Social Anxiety Disorder (SAD), has determined the application not approvable. While indicating that data from one of the two required pivotal studies supported the application, the agency raised questions related to the reliability of patient data at one study center in the second pivotal study. Both studies were conducted in Europe. By eliminating the study center in question the statistical significance (p-value) of the study declines to 0.06 which the FDA no longer accepted as a positive pivotal study. Forest is reviewing the FDA's analysis and will determine the appropriate next steps to address the non-approvable letter in the coming months, which may include additional discussions with the FDA pertaining to data from the excluded center or conducting an additional pivotal study. Lexapro is indicated for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder in adults. It is also approved in Europe for Depression, Social Anxiety Disorder and Panic Disorder where it is marketed by H. Lundbeck A/S.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that affect our business, including risk factors listed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2004, and on form 10-Q for the periods ended June 30, 2004, September 30, 2004 and December 31, 2004. Actual results may differ materially from those projected.

Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO

Forest Laboratories, Inc.

CONTACT: Charles E. Trian, Vice President, Investor Relations of ForestLaboratories Inc., +1-212-224-6714, Charles.Triano@frx.com



Read at AP
Read at The Street.com
Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES